0001567619-22-021928.txt : 20221221
0001567619-22-021928.hdr.sgml : 20221221
20221221160722
ACCESSION NUMBER: 0001567619-22-021928
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20221219
FILED AS OF DATE: 20221221
DATE AS OF CHANGE: 20221221
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Wang Xiaolin
CENTRAL INDEX KEY: 0001849181
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39219
FILM NUMBER: 221478536
MAIL ADDRESS:
STREET 1: C/O REVOLUTION MEDICINES, INC.
STREET 2: 700 SAGINAW DRIVE
CITY: REDWOOD CITY
STATE: CA
ZIP: 94063
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Revolution Medicines, Inc.
CENTRAL INDEX KEY: 0001628171
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 472029180
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 700 SAGINAW DR
CITY: REDWOOD CITY
STATE: CA
ZIP: 94063
BUSINESS PHONE: 415-766-3638
MAIL ADDRESS:
STREET 1: 700 SAGINAW DR
CITY: REDWOOD CITY
STATE: CA
ZIP: 94063
4
1
doc1.xml
FORM 4
X0306
4
2022-12-19
0
0001628171
Revolution Medicines, Inc.
RVMD
0001849181
Wang Xiaolin
C/O REVOLUTION MEDICINES, INC.
700 SAGINAW DRIVE
REDWOOD CITY
CA
94063
0
1
0
0
See Remarks
Common Stock
2022-12-19
4
S
0
708
22.9398
D
30527
D
Pursuant to an automatic sell-to-cover imposed by the terms of the restricted stock units ("RSUs") award, the shares were sold following the vesting of the RSUs solely to cover applicable withholding taxes.
This transaction was executed in multiple trades in prices ranging from $22.4706 to $22.96, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
Includes 22,550 RSUs.
EVP, Clinical Development
/s/ Jack Anders, as Attorney-in-fact for Xiaolin Wang
2022-12-21